Skip to main content

Advertisement

Table 3 Any osteoporotic fracture outcomes according to baseline characteristics and treatment group

From: The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial

Baseline characteristic   B-Vitamins Placebo p-value P-value for interaction
(n = 4089) (n = 4075) (log-rank test)
N (%) N (%)  
Sex Male 27 (1.0) 28 (1.1) 0.90 0.50
  Female 40 (2.7) 50 (3.4) 0.21  
Age <65 yrs 12 (0.6) 11 (0.5) 0.90 0.57
  > = 65 yrs 55 (2.8) 67 (3.5) 0.28  
Ethnicity Western European 48 (2.9) 57(3.5) 0.35 0.65
  Oriental 9 (0.9) 6 (0.6) 0.42  
  South Asian 4 (0.4) 3 (0.3) 0.74  
  Other 1 (0.4) 5 (1.7) 0.12  
Oxford Handicap Score > = 3 14 (1.5) 21 (2.2) 0.18 0.34
  <3 51 (1.7) 56 (1.9) 0.63  
Smoking (ever) Yes 36 (1.8) 36 (1.8) 0.96 0.30
  No 31 (1.5) 42 (2.1) 0.16  
Alcohol (any) Yes 26 (2.2) 28 (2.5) 0.71 0.76
  No 41 (1.4) 50 (1.7) 0.32  
Diabetes Yes 9 (0.9) 15 (1.6) 0.21 0.34
  No 58 (1.9) 63 (2.0) 0.62  
Stroke Yes 13 (2.1) 15 (2.3) 0.75 0.94
  No 54 (1.6) 63 (1.9) 0.38  
Myocardial infarction Yes 8 (2.7) 7 (2.3) 0.71 0.49
  No 59 (1.6) 71 (1.9) 0.25  
Hypertension Yes 48 (1.7) 57 (2.0) 0.40 0.98
  No 19 (1.6) 21 (1.8) 0.64  
Depression Yes 8 (2.9) 8 (3.0) 0.83 0.51
  No 35 (1.0) 49 (1.5) 0.14  
Antidepressant medication Yes 11 (4.0) 13 (4.6) 0.67 0.99
  No 56 (1.5) 65 (1.8) 0.37  
Corticosteroid medication Yes 10 (3.3) 13 (4.7) 0.05 0.98
  No 57 (1.5) 65 (1.7) 0.46  
Osteoporosis Medication Yes 4 (1.3) 5 (1.8) 0.37 0.62
  No 30 (0.8) 31 (0.8) 0.44  
Homocysteine < median 10 (3.2) 10 (3.5) 0.77 0.81
(median 12.6 micromol/L) (n = 595)
  > = median 8 (2.7) 12 (3.8) 0.53  
(n = 610)